Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06139094 · ClinicalTrials.gov registry record
MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR
A clinical trial, sponsored by Genetesis.
- Completed
- Registry status
- 48
- Enrollment target
NCT06139094: Completed study, sponsored by Genetesis.
NCT06139094 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06139094 has completed, sponsored by Genetesis.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
This study will be an observational registry to investigate the ability of magnetocardiography (MCG) in determining the presence of myocardial ischemia with the absence of obstructive coronary artery disease, by using an invasive reference standard coronary flow reserve (CFR) measured using thermodilution for diagnosis. The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with cloud processing software. A CardioFlux scan appointment shall last approximately 15 minutes in duration and include a patient questionnaire following the scan.
Primary Outcome
This observational registry study focuses on investigating the efficacy of magnetocardiography (MCG) in detecting myocardial ischemia secondary to coronary microvascular dysfunction (CMD) in the absence of obstructive coronary artery disease.
Interventions
- DEVICE CardioFlux Magnetocardiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2024-05-13 |
What the finished NCT06139094 record still lists
NCT06139094 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CardioFlux Magnetocardiography is the first listed.
NCT06139094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06139094 about?
NCT06139094 is a clinical study titled "MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR". This study will be an observational registry to investigate the ability of magnetocardiography (MCG) in determining the presence of myocardial ischemia with the absence of obstructive coronary artery disease, by using an invasive reference standard coronary flow reserve (CFR) measured using thermodi...
What is the current status of trial NCT06139094?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2023-12-20. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT06139094?
The interventions under investigation include: CardioFlux Magnetocardiography (DEVICE).
Who is sponsoring clinical trial NCT06139094?
This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI